
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders, with a primary emphasis on its product candidate, Neflamapimod. The company has completed enrollment in a Phase 2a study for the treatment of non-fluent variant primary progressive aphasia and is preparing for a pivotal trial to assess Neflamapimod in patients with dementia with Lewy bodies. Additionally, CervoMed has plans to start a clinical study for Neflamapimod in amyotrophic lateral sclerosis by the end of this year.
Bears say
CervoMed is facing significant challenges moving forward, as evidenced by their recent financial performance and the failure of their drug candidate, Neflamapimod, to replicate positive results in their Phase 2a study. The data shows that the drug was not effective in patients with Alzheimer's co-pathology and lower-than-expected drug exposure. Additionally, their current valuation is based on optimistic assumptions, and there are numerous risks that could hinder their success, including delays in their Phase 3 trial and failure to secure regulatory approval.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares